Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
Takeda Ordered To Pay AbbVie $480m For Failing To Supply Lupron
AbbVie stands to potentially receive significant damages, possibly amounting to hundreds of millions of dollars, due to a contractual manufacturing ...
BlueWhale Bio Emerges With $18m To Tackle Cell Therapy Manufacturing Challenges
BlueWhale Bio, a spinout from the University of Pennsylvania, has emerged with a bold mission to tackle bottlenecks in the ...
PhRMA Launches New Ad Campaign Against PBMs Over Pharmacy Choice
PhRMA has once again mobilized its attack ad team to launch a fresh assault on pharmacy benefit managers (PBMs), this ...
Permira Buys Out CRO Ergomed For £703 Million In Private Deal
Permira, the London-based private equity firm, has made a substantial investment of 703 million pounds sterling (equivalent to $886 million) ...
Vaxart’s Oral Norovirus Vaccine Misses Primary Endpoint But Shows Some Efficacy In Phase 2
Vaxart finds itself in a precarious position as it grapples with mixed results for its oral monovalent norovirus vaccine candidate, ...
Pfizer’s Lyme Vaccine Shows Strong Booster And Pediatric Effects In Phase 2
Pfizer and Valneva are making strides in their Lyme disease vaccine program, achieving a significant milestone by demonstrating the safety ...
Roche’s $310 Million Gamble On Alnylam Pays Off As Hypertension Drug Shows Promise In Phase 2
Roche’s recent investment of $310 million into metabolic therapy is yielding positive results, as its collaboration with Alnylam in the ...
Moody’s Says IRA Price Negotiations Will Have A Modest Impact On Pharma Industry By 2026
With the Centers for Medicare & Medicaid Services (CMS) unveiling the initial list of 10 drugs set to undergo Medicare ...
Janssen CarePath Patient Assistance Program Hit By Data Breach, IBM Reports
A technical vulnerability has led to “unauthorized access” to personal data within Johnson & Johnson’s Janssen CarePath patient assistance program, ...
Singapore’s Hiro Acquires US Oncology CRO To Expand Its Global Footprint
Singapore-based Harvest Integrated Research Organization, known as HiRO, is making a significant move to bolster its global presence through the ...
Novo Nordisk Renews Partnership With Harvard And Broad Institute To Discover New Diabetes And Heart Disease Drugs
Novo Nordisk has announced a collaborative effort with Harvard University and the Broad Institute of MIT to embark on a ...
Janssen Drops Cidara’s Flu Medicine After Disappointing Phase 2 Results
Janssen is honoring its 2021 agreement with Cidara Therapeutics regarding the development of CD388, a flu prophylaxis treatment. However, Janssen ...
Royalty Pharma Pays $150M To Ascendis For A Share Of Skytrofa Sales
Royalty Pharma, renowned for its investments in exchange for long-term drug royalties, has entered into a collaboration with Ascendis Pharma ...
Astrazeneca Suffers Setback As FDA Rejects Ultomiris For Rare Autoimmune Disease
AstraZeneca’s plans to expand the use of Ultomiris in the United States have encountered a setback, as the FDA issued ...
Abbott Partners With Bigfoot Biomedical To Integrate Diabetes Devices
Abbott has made a significant move by acquiring Bigfoot Biomedical, a diabetes management technology maker. While the financial terms of ...
Medicare Price Negotiations Could Slash Biotech R&D Spending, Gilead-Funded Study Warns
The Inflation Reduction Act (IRA) is projected to have a more significant impact on pharmaceutical research and development (R&D) than ...
Moderna Claims New COVID-19 Vaccine Can Protect Against Pirola Variant
Moderna is vigorously advocating for the expedited approval of its updated COVID-19 vaccine in preparation for the upcoming fall vaccination ...
J&J Gives Up On $230M Blood Pressure Drug After Disappointing Trial Results
Johnson & Johnson (J&J) is stepping back from its $230 million investment in a blood pressure treatment, aprocitentan, and returning ...
Nimbus Raises $210M To Advance Small Molecule Pipeline, Honors Late Founder
Nimbus Therapeutics, with its experienced leadership, well-established R&D platform, and substantial financing, appears well-positioned for success in the public markets. ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
GSK Teams Up With Ex-Basketball Star To Raise Awareness Of RSV, A Deadly Virus For Babies
GSK is intensifying its campaign to raise awareness about respiratory syncytial virus (RSV) and promote its RSV vaccine, Arexvy. The ...
Seagen, Genmab’s Tivdak shows survival benefit in cervical cancer phase 3 trial
Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...
Novartis sues U.S. government over IRA price negotiations for Entresto
Novartis has taken legal action against the U.S. government in response to the Inflation Reduction Act (IRA), becoming the latest ...
Nestlé abandons $2 billion peanut allergy drug Palforzia after disappointing sales and safety issues
Nestlé has completed the sale of its peanut allergy drug, Palforzia, to the U.S.-based allergy specialist Stallergenes Greer for an ...
Tonix’s long COVID drug fails in pain but shows promise in fatigue
Tonix Pharmaceuticals’ experimental treatment for long COVID with fibromyalgia-like symptoms, TNX-102 SL, did not demonstrate a statistically significant improvement in ...
CanSino Biologics eyes more mRNA vaccine deals after AstraZeneca pact
CanSino’s recent collaboration with AstraZeneca in mRNA manufacturing is just the beginning of their ambitions in this field, according to ...
BioCardia’s cell therapy fails to improve heart failure outcomes in Phase 3 trial
BioCardia’s attempts to revive its paused phase 3 heart failure trial have hit a major setback, as results fail to ...
Star Therapeutics raises $90M to expand its portfolio of antibody therapies for unmet needs
Star Therapeutics has secured an impressive $90 million in funding, a testament to its commitment to advancing its portfolio companies ...
BMS acquires regional rights to Zenas’ obexelimab, a bifunctional antibody for autoimmune diseases
Zenas BioPharma has made a strategic move by transferring regional rights for its bifunctional monoclonal antibody, obexelimab. Bristol Myers Squibb ...
Amgen’s Otezla holds its ground against BMS’ Sotyktu in oral plaque psoriasis market, leaving room for J&J’s potential game-changer
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
